Genio's Efficacy in Treating OSA
The DREAM study met both its primary and secondary endpoints with a strong AHI responder rate of 63.5% and an ODI responder rate of 71.3%. The study demonstrated a 70.8% median AHI reduction, with Genio uniquely maintaining its efficacy irrespective of a patient's sleeping position.
U.S. Market Launch Preparation
Nyxoah is prepared for a U.S. market launch with a trained team of 50 commercial members and identified CPT code 64568 for reimbursement. The company expects to receive FDA approval by the end of March 2025.
Expansion in Europe and Beyond
The company launched Genio in the United Kingdom and the United Arab Emirates, with promising initial results. Revenue in Europe grew by 18% over 2023, reaching €5.1 million for the full year 2024.
Strong Cash Position
Nyxoah's cash position remained strong at €85.6 million at December 31, 2024, compared to €57.7 million at the end of 2023, including proceeds from a €24.6 million ATM equity raise.